New unit to bring Novo Nordisk closer to goal of using RNA and gene therapies across all treatment areas

Novo Nordisk has begun the work of establishing a new internal unit as part of a "significant investment" in RNA and gene therapies. The long-term aim is to use these therapies across all treatment areas.

Photo: Novo Nordisk / PR

Novo Nordisk, Denmark's biggest pharmaceutical company, has established a new unit with the ambition of making RNA and gene therapy available across all of its therapy areas, Senior Vice President of Global Research Technologies at Novo Nordisk tells Medwatch.

"One of the main reasons we are taking this leap is our belief that RNA and gene therapy could be used within all of Novo Nordisk's therapy areas," Fogh Iversen says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs